Cancel
Aridis Pharmaceuticals
See Linkedin
Aridis Pharmaceuticals Employees
6 people indexed:
-
Elizabeth Leininger, Ph.D.
Vice President of Regulatory Affairs and Quality
w7k392t4k.v1.k3@q2jj0jtkk6x0.zw4 Sign up to see email94xvtk2kj.tx.9f@5jqz425buwwq.4wf Sign up to see email -
Fred Kurland, J.D., M.B.A.
Senior Financial Consultant
076q29w.q.1.t.3.17@veyvgtez81ty.z2e Sign up to see email7218t4w.2.t.2.0.4e@650vztg48z9x.6qt Sign up to see email -
7z0v3.n.lz@y61b2b33xqkt.329 Sign up to see email
-
Jeffrey J. Fessler, J.D.
Acting General Counsel
n.uxw4wwx.b.wg@5twwx35z9w78.13x Sign up to see email2.5881yw3.8.qv@5g085237yu3k.6bt Sign up to see email -
Steven Chamow, Ph.D.
Vice President of Research and Development
u06g1v.e3.8x@b13gy5bfn354.bnk Sign up to see emaile54q37.fk.z5@tjuk9u7vn64q.kkl Sign up to see email -
j.yyj892.28.38@67jby3q9z03y.451 Sign up to see email
Aridis Pharmaceuticals Company Information
Aridis Pharmaceuticals is dedicated to developing novel, differentiated therapies for infectious diseases. The company focuses on the discovery and development of monoclonal antibodies derived from convalescent infected patients. Its pipeline includes AR-301 (Tosatoxumab), AR-320 (Suvratoxumab), AR-501 (Panaecin™), and AR-701 (COVID-19 mAb). AR-301 targets S. aureus alpha-toxin and is in Phase 3 clinical trials for treating ventilator-associated pneumonia. AR-320 is designed as a pre-emptive treatment for S. aureus in mechanically ventilated ICU patients. AR-501 is an inhalable form of gallium citrate, effective against antibiotic-resistant bacteria. AR-701 comprises monoclonal antibodies that target SARS-CoV-2 envelope proteins. Aridis utilizes proprietary technology platforms ⅄PEXTM and MabIgX® for rapid antibody discovery. The company’s therapeutic areas include hospital-acquired infections, cystic fibrosis, and COVID-19.
Report inaccurate information
Report inaccurate information
